Recombinant Rat Dynamin-like 120 kDa protein, mitochondrial (Opa1)

Introduction to Recombinant Rat Dynamin-like 120 kDa protein, mitochondrial (OPA1)

Recombinant Rat Dynamin-like 120 kDa protein, mitochondrial (OPA1) is a laboratory-produced version of the naturally occurring OPA1 protein found in rats (Rattus norvegicus). This recombinant protein, commercially available as product number RPE291Ra01, is produced through prokaryotic expression in Escherichia coli systems . It encompasses a specific fragment of the native rat OPA1 protein, spanning from amino acid residues Gln285 to Glu561, and includes His and TRxA tags to facilitate purification and detection in experimental settings .

The native OPA1 protein functions as a dynamin-related GTPase that regulates mitochondrial fusion and cristae structure in the inner mitochondrial membrane (IMM). This multifunctional protein contributes significantly to ATP synthesis and apoptosis regulation, making it a crucial component for cellular energy metabolism and programmed cell death pathways . In its natural context, OPA1 exists in multiple isoforms resulting from alternative splicing and proteolytic processing, with eight transcript variants reported in humans .

The significance of OPA1 extends beyond normal cellular physiology into pathological conditions. In humans, mutations in the OPA1 gene have been implicated in dominant optic atrophy (DOA), a condition characterized by progressive loss of visual acuity due to optic nerve degeneration . The recombinant rat version of this protein serves as an invaluable tool for researchers investigating mitochondrial dynamics, energy metabolism, and disease models related to mitochondrial dysfunction.

Function and Mechanism of Action

Recombinant Rat OPA1 retains the core functional domains of the native protein, making it suitable for investigating the molecular mechanisms underlying OPA1's biological activities. In its native cellular context, OPA1 serves as a multifunctional GTPase involved in several critical mitochondrial processes.

OPA1 also plays a crucial role in maintaining cristae structure within mitochondria. The cristae are folds of the inner mitochondrial membrane that house the respiratory chain complexes. OPA1 mediates cristae remodeling by oligomerizing at cristae junctions, with this oligomerization typically involving two L-OPA1 molecules and one S-OPA1 molecule . This structural arrangement is essential for maintaining optimal cristae architecture and, consequently, efficient oxidative phosphorylation.

Additionally, OPA1 contributes to the regulation of apoptosis by controlling the release of cytochrome c from mitochondria. By maintaining tight cristae junctions, OPA1 oligomers limit the mobilization of cytochrome c from the cristae spaces to the intermembrane space, thereby preventing its release into the cytosol and the subsequent activation of caspases that execute apoptosis . This function highlights the protein's role in cell survival and programmed cell death decisions.

OPA1 also responds to cellular stress conditions. Under low-energy substrate availability, mitochondrial SLC25A transporters can detect these conditions and stimulate OPA1 oligomerization . This leads to tightening of the cristae, enhanced assembly of ATP synthase, and increased ATP production, representing an adaptive response to energy stress . Conversely, stress conditions that compromise mitochondrial membrane potential can activate the protease OMA1, leading to increased processing of L-OPA1 to S-OPA1, which limits fusion and can promote mitochondrial fragmentation .

Recent research has also identified OPA1 as a regulator of T-helper Th17 cells, where it mediates mitochondrial membrane remodeling required for interleukin-17 (IL-17) production . This finding expands the known functions of OPA1 beyond mitochondrial dynamics into immune system regulation.

Production and Purification Methods

The specific fragment of OPA1 expressed (Gln285~Glu561) represents a portion of the protein that contains critical functional domains while excluding regions that might compromise expression or stability in a bacterial system . The inclusion of His and TRxA tags serves multiple purposes in the production and purification process. The histidine (His) tag facilitates purification through immobilized metal affinity chromatography (IMAC), allowing the recombinant protein to be selectively bound to metal resins and subsequently eluted with imidazole or a similar competitor. The thioredoxin (TRxA) tag often enhances protein solubility and stability in bacterial expression systems, potentially increasing yield and quality.

The purification process typically involves several steps beyond initial IMAC separation, which may include ion exchange chromatography, size exclusion chromatography, or other techniques to achieve the high purity (>95%) reported for the commercial product . Following purification, the protein is formulated in a stabilizing buffer and lyophilized to produce the freeze-dried powder form in which it is commercially available.

Applications in Research

Recombinant Rat OPA1 serves as a versatile tool in various experimental approaches, enabling researchers to investigate mitochondrial biology and related disease mechanisms. Its commercial availability facilitates consistent and reproducible research across different laboratories.

In immunological applications, the recombinant protein can function as an immunogen for antibody production, allowing the development of specific antibodies against rat OPA1 for immunodetection techniques . These antibodies can then be used in studies examining OPA1 expression, localization, and modifications in different tissues or under various experimental conditions.

The protein also serves as a positive control in analytical techniques such as sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting (WB) . This application is particularly valuable for validating experimental procedures and ensuring the reliability of results when studying endogenous OPA1 in rat samples.

Beyond these specific applications, Recombinant Rat OPA1 can be employed in various research contexts, including:

1. Structural Studies: Investigating the conformational states and structural dynamics of OPA1 using techniques such as X-ray crystallography or cryo-electron microscopy.

2. Protein-Protein Interaction Studies: Identifying and characterizing interactions between OPA1 and other proteins involved in mitochondrial dynamics or related cellular processes.

3. Enzymatic Assays: Measuring the GTPase activity of OPA1 and evaluating how it is affected by various experimental conditions or potential inhibitors/activators.

4. Disease Modeling: Exploring how OPA1 function is altered in models of diseases associated with mitochondrial dysfunction, such as optic atrophy, neurodegeneration, or metabolic disorders .

5. Drug Discovery: Screening for compounds that might modulate OPA1 function or processing as potential therapeutic agents for diseases involving mitochondrial dynamics dysregulation .

Role in Mitochondrial Dynamics

Mitochondria constantly undergo fusion and fission events in response to cellular needs and environmental conditions. OPA1 plays a central role in this dynamic equilibrium, specifically in mediating the fusion of inner mitochondrial membranes . The interplay between long forms of OPA1 (L-OPA1) and short forms (S-OPA1) is crucial for this regulation.

L-OPA1, which remains anchored to the inner mitochondrial membrane through its transmembrane domain, is required for mitochondrial fusion . In cooperation with mitofusins (MFN1 and MFN2), which mediate outer membrane fusion, L-OPA1 facilitates the merging of inner membranes, allowing content mixing between mitochondria . This fusion process is essential for maintaining mitochondrial DNA integrity, distributing metabolites and proteins throughout the mitochondrial network, and compensating for functional defects in individual mitochondria.

In contrast, S-OPA1, which results from proteolytic processing of L-OPA1 by the peptidases YME1L and OMA1, lacks the transmembrane domain and localizes to the intermembrane space . While S-OPA1 alone is insufficient for fusion, it can limit fusion efficiency and, under certain conditions, may facilitate mitochondrial fission . Studies have shown that overexpression of S-OPA1 leads to mitochondrial fragmentation, while expression of L-OPA1 that lacks cleavage sites promotes mitochondrial fusion and can even induce hyperfusion under specific stress conditions .

The proteolytic processing of OPA1 is tightly regulated and responds to various cellular signals. YME1L-mediated processing occurs under basal conditions and may be linked to the quality control of OPA1 and the fine-tuning of mitochondrial dynamics . In contrast, OMA1-mediated processing is activated under stress conditions, such as mitochondrial membrane potential loss or ATP depletion . This stress-induced processing leads to increased conversion of L-OPA1 to S-OPA1, limiting fusion and potentially promoting fission, which may represent an adaptive response to segregate damaged mitochondria for subsequent removal by mitophagy.

Relevance to Disease Models

Recombinant Rat OPA1 serves as a valuable tool for investigating disease models related to mitochondrial dysfunction, particularly those involving alterations in mitochondrial dynamics or OPA1 function. Research in this area has significant implications for understanding and potentially treating various human diseases.

Mutations in the human OPA1 gene are the primary cause of autosomal dominant optic atrophy (ADOA), a condition characterized by the degeneration of retinal ganglion cells and the optic nerve, resulting in progressive vision loss . While ADOA primarily affects vision, patients with OPA1 mutations may also experience a range of additional symptoms, including deafness, ataxia, sensorimotor neuropathy, progressive external ophthalmoplegia, and mitochondrial myopathy, reflecting the widespread importance of OPA1 function throughout the body .

These OPA1-related diseases can be modeled using rat systems, where the recombinant protein plays a crucial role in mechanistic studies. In such models, heterozygous Opa1 mutations replicate many features of human ADOA and may also lead to additional phenotypes such as cardiomyopathy . These models exhibit abnormal mitochondrial morphology and dysfunction, including defects in oxidative phosphorylation and mitochondrial DNA instability.

Beyond its direct role in genetic diseases, dysregulation of OPA1 processing and function has been implicated in various other pathological conditions. Excessive processing of OPA1 by the stress-activated protease OMA1, leading to mitochondrial fragmentation, has been observed in models of neurodegenerative diseases, ischemia-reperfusion injury, and metabolic disorders . This suggests that maintaining proper OPA1 function and mitochondrial dynamics may be broadly relevant to human health and disease.

Recent research has also suggested a potential association between mitochondrial fusion involving OPA1 and MFN2 and Parkinson's disease . This finding expands the relevance of OPA1 research to a broader range of neurodegenerative conditions and highlights the importance of maintaining proper mitochondrial dynamics for neuronal health.

In the therapeutic realm, Stoke Therapeutics is evaluating the splice-switching antisense oligonucleotide STK-002 as a potential treatment for DOA . This approach aims to reduce poison exon inclusion in the OPA1 transcript, leading to increased functional OPA1 protein levels. Such therapeutic strategies highlight the potential clinical applications of OPA1 research using recombinant proteins for functional studies.

Comparative Analysis with OPA1 from Other Species

Recombinant Rat OPA1 provides an opportunity to compare the structure, function, and regulation of this protein across different species. Such comparative analyses can reveal evolutionarily conserved features that are likely to be functionally critical, as well as species-specific adaptations that might reflect different physiological demands or regulatory mechanisms.

The OPA1 protein is highly conserved across mammalian species, reflecting its essential role in mitochondrial function. Human OPA1, rat OPA1, and OPA1 from other mammals such as Sumatran orangutan share significant sequence homology and functional similarities . All maintain the core GTPase domain characteristic of dynamin-related proteins and possess similar mechanisms of action in regulating mitochondrial fusion and cristae morphology.

In Sumatran orangutan, as in humans and rats, OPA1 exists in both long (L-OPA1) and short (S-OPA1) forms, with the long form tethered to the inner mitochondrial membrane and the short form resulting from proteolytic cleavage and localizing to the intermembrane space . The balance between these forms is crucial for proper mitochondrial function across species, with excess levels of S-OPA1 leading to impaired mitochondrial fusion .

The proteolytic processing of OPA1 by peptidases such as YME1L and OMA1 appears to be conserved across mammals, suggesting that this regulatory mechanism is fundamental to OPA1 function . Similarly, the role of OPA1 in cristae remodeling and cytochrome c release during apoptosis is observed across species, highlighting the evolutionary importance of this function .

Despite these similarities, there may be subtle differences in OPA1 regulation and processing between species. For instance, the specific patterns of alternative splicing, which generates different OPA1 isoforms, may show species-specific variations. These differences could affect how OPA1 responds to various cellular signals and stresses in different experimental models.

Understanding these cross-species similarities and differences is important when using rat OPA1 as a model for studying human diseases or when translating findings from rat studies to human applications. Recombinant proteins from different species enable direct comparative studies that can illuminate these aspects.

Future Research Directions

Research utilizing Recombinant Rat OPA1 continues to expand our understanding of mitochondrial dynamics and related diseases. Several promising directions for future investigation have emerged, offering potential for both basic scientific advances and therapeutic applications.

One significant area of ongoing research focuses on preventing pathological OPA1 processing. Since excessive processing of L-OPA1 to S-OPA1 by the stress-activated protease OMA1 can lead to mitochondrial fragmentation and contribute to cell death in various disease contexts, interventions that modulate this process represent an exciting therapeutic avenue . Specific inhibitors of OMA1 or compounds that stabilize L-OPA1 against proteolytic processing could potentially preserve mitochondrial integrity in conditions ranging from neurodegenerative diseases to ischemia-reperfusion injury.

Another promising approach involves antisense oligonucleotide therapy. For instance, Stoke Therapeutics is evaluating a splice-switching antisense oligonucleotide (STK-002) as a potential treatment for dominant optic atrophy . This approach aims to reduce the inclusion of a "poison exon" in the OPA1 transcript, thereby increasing functional OPA1 protein levels. While this specific therapy targets human OPA1, similar approaches could be developed for experimental models using rat OPA1, potentially offering insights into the efficacy and mechanisms of such interventions.

Further research is also needed to elucidate the precise mechanisms by which OPA1 mediates inner membrane fusion and maintains cristae structure. Structural studies of OPA1, including its different forms and oligomeric states, could provide crucial insights into these processes. Recombinant OPA1 offers a valuable tool for such structural investigations, potentially revealing targets for specific molecular interventions.

The interaction between OPA1 and other proteins involved in mitochondrial dynamics, such as mitofusins, DRP1, and various proteases, represents another important area for investigation. Mapping these interaction networks and understanding how they respond to different cellular conditions could reveal new regulatory mechanisms and potential therapeutic targets.

Finally, the role of OPA1 in specific cellular contexts and disease states requires further exploration. For instance, the function of OPA1 in immune cells, where research has identified a role in T-helper Th17 cell regulation and interleukin-17 production , may have implications for autoimmune diseases and inflammation. Similarly, the involvement of OPA1 in metabolic regulation and adaptation to energy stress suggests potential relevance to metabolic disorders and aging-related decline.